Polycomb Repressive Complex 2 Is a Barrier to KRAS-Driven Inflammation and Epithelial-Mesenchymal Transition in Non-Small-Cell Lung Cancer

Cancer Cell

Volumn 29, Issue 1, 2016, Pages 17-31

  Serresi, Michela ^a   Gargiulo, Gaetano ^a   Proost, Natalie ^a   Siteur, Bjorn ^a   Cesaroni, Matteo ^b   Koppens, Martijn ^a   Xie, Huafeng ^c   Sutherland, Kate D ^a,e,f   Hulsman, Danielle ^a   Citterio, Elisabetta ^a   Orkin, Stuart ^c   Berns, Anton ^a   van Lohuizen, Maarten ^a,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d Cancer Genomics Center (CGCnl)   (Netherlands)

^e WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; K RAS PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; WNT PROTEIN; EZH2 PROTEIN, HUMAN; EZH2 PROTEIN, MOUSE; HISTONE; KRAS PROTEIN, HUMAN; KRAS2 PROTEIN, MOUSE; PROTEIN P21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CHROMATIN; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; INFLAMMATION; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MACROPHAGE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN METHYLATION; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; ACETYLATION; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

ACETYLATION; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; HISTONES; HUMANS; INFLAMMATION; MICE, TRANSGENIC; POLYCOMB REPRESSIVE COMPLEX 2; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 84958787612     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.12.006     Document Type: Article

References (61)

1. Barbie D.A., Tamayo P., Boehm J.S., Kim S.Y., Moody S.E., Dunn I.F., Schinzel A.C., Sandy P., Meylan E., Scholl C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462:108-112.
2. Beyer T.A., Weiss A., Khomchuk Y., Huang K., Ogunjimi A.A., Varelas X., Wrana J.L. Switch enhancers interpret TGF-β and Hippo signaling to control cell fate in human embryonic stem cells. Cell Rep. 2013, 5:1611-1624.
3. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
4. Bracken A.P., Kleine-Kohlbrecher D., Dietrich N., Pasini D., Gargiulo G., Beekman C., Theilgaard-Mönch K., Minucci S., Porse B.T., Marine J.-C., et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 2007, 21:525-530.
5. Bruggeman S.W.M., Hulsman D., Tanger E., Buckle T., Blom M., Zevenhoven J., van Tellingen O., Van Lohuizen M. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 2007, 12:328-341.
6. Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014, 511:543-550.
7. Chen J., Xu H., Zou X., Wang J., Zhu Y., Chen H., Shen B., Deng X., Zhou A., Chin E., et al. Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells. Cancer Res. 2014, 74:4353-4363.
8. De Raedt T., Beert E., Pasmant E., Luscan A., Brems H., Ortonne N., Helin K., Hornick J.L., Mautner V., Kehrer-Sawatzki H., et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 2014, 514:247-251.
9. Desai T.J., Brownfield D.G., Krasnow M.A. Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 2014, 507:190-194.
10. Di Mitri D., Toso A., Chen J.J., Sarti M., Pinton S., Jost T.R., D'Antuono R., Montani E., Garcia-Escudero R., Guccini I., et al. Tumour-infiltrating Gr-1(+) myeloid cells antagonize senescence in cancer. Nature 2014, 515:134-137.
11. Fillmore C.M., Xu C., Desai P.T., Berry J.M., Rowbotham S.P., Lin Y.-J., Zhang H., Marquez V.E., Hammerman P.S., Wong K.-K., et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 2015, 520:239-242.
12. Friedman J.M., Liang G., Liu C.-C., Wolff E.M., Tsai Y.C., Ye W., Zhou X., Jones P.A. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 2009, 69:2623-2629.
13. Gargiulo G., Levy S., Bucci G., Romanenghi M., Fornasari L., Beeson K.Y., Goldberg S.M., Cesaroni M., Ballarini M., Santoro F., et al. NA-Seq: a discovery tool for the analysis of chromatin structure and dynamics during differentiation. Dev. Cell 2009, 16:466-481.
14. Gargiulo G., Cesaroni M., Serresi M., de Vries N., Hulsman D., Bruggeman S.W.M., Lancini C., Van Lohuizen M. In vivo RNAi screen for BMI1 targets identifies TGF-β/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis. Cancer Cell 2013, 23:660-676.
15. Gazin C., Wajapeyee N., Gobeil S., Virbasius C.-M., Green M.R. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 2007, 449:1073-1077.
16. Hock H. A complex Polycomb issue: the two faces of EZH2 in cancer. Genes Dev. 2012, 26:751-755.
17. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., Jacks T., Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001, 15:3243-3248.
18. Jacobs J.J.L., Kieboom K., Marino S., DePinho R.A., Van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168.
19. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001, 410:1111-1116.
20. Kapoor A., Yao W., Ying H., Hua S., Liewen A., Wang Q., Zhong Y., Wu C.-J., Sadanandam A., Hu B., et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 2014, 158:185-197.
21. Kim E., Kim M., Woo D.-H., Shin Y., Shin J., Chang N., Oh Y.T., Kim H., Rheey J., Nakano I., et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013, 23:839-852.
22. Kim M., Kim T., Johnson R.L., Lim D.-S. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ. Cell Rep. 2015, 11:270-282.
23. Knutson S.K., Warholic N.M., Wigle T.J., Klaus C.R., Allain C.J., Raimondi A., Porter Scott M., Chesworth R., Moyer M.P., Copeland R.A., et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA 2013, 110:7922-7927.
24. Koppens M., Van Lohuizen M. Context-dependent actions of Polycomb repressors in cancer. Oncogene 2015, 1-12. 10.1038/onc.2015.195.
25. Kuilman T., Michaloglou C., Mooi W.J., Peeper D.S. The essence of senescence. Genes Dev. 2010, 24:2463-2479.
26. Lee K.E., Bar-Sagi D. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell 2010, 18:448-458.
27. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Klöppel G., Yoshimura A., Reindl W., Sipos B., Akira S., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19:456-469.
28. Li Z., Xu L., Tang N., Xu Y., Ye X., Shen S., Niu X., Lu S., Chen Z. The polycomb group protein EZH2 inhibits lung cancer cell growth by repressing the transcription factor Nrf2. FEBS Lett. 2014, 588:3000-3007.
29. Ling J., Kang Y., Zhao R., Xia Q., Lee D.-F., Chang Z., Li J., Peng B., Fleming J.B., Wang H., et al. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:105-120.
30. López-Novoa J.M., Nieto M.A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol. Med. 2009, 1:303-314.
31. Mallen-St Clair J., Soydaner-Azeloglu R., Lee K.E., Taylor L., Livanos A., Pylayeva-Gupta Y., Miller G., Margueron R., Reinberg D., Bar-Sagi D. EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev. 2012, 26:439-444.
32. Margueron R., Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
33. McCabe M.T., Ott H.M., Ganji G., Korenchuk S., Thompson C., Van Aller G.S., Liu Y., Graves A.P., Pietra Della A., Diaz E., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
34. Montgomery N.D., Yee D., Chen A., Kalantry S., Chamberlain S.J., Otte A.P., Magnuson T. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. Curr. Biol. 2005, 15:942-947.
35. Moroishi T., Hansen C.G., Guan K.-L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 2015, 15:73-79.
36. Oktyabri D., Tange S., Terashima M., Ishimura A., Suzuki T. EED regulates epithelial-mesenchymal transition of cancer cells induced by TGF-β. Biochem. Biophys. Res. Commun. 2014, 453:124-130.
37. Pasini D., Bracken A.P., Hansen J.B., Capillo M., Helin K. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol. Cell Biol. 2007, 27:3769-3779.
38. Pasini D., Malatesta M., Jung H.R., Walfridsson J., Willer A., Olsson L., Skotte J., Wutz A., Porse B., Jensen O.N., et al. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res. 2010, 38:4958-4969.
39. Pengelly A.R., Copur Ö., Jäckle H., Herzig A., Müller J. A histone mutant reproduces the phenotype caused by loss of histone-modifying factor Polycomb. Science 2013, 339:698-699.
40. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
41. Reynolds N., Salmon-Divon M., Dvinge H., Hynes-Allen A., Balasooriya G., Leaford D., Behrens A., Bertone P., Hendrich B. NuRD-mediated deacetylation of H3K27 facilitates recruitment of Polycomb Repressive Complex 2 to direct gene repression. EMBO J. 2012, 31:593-605.
42. Rock K.L., Latz E., Ontiveros F., Kono H. The sterile inflammatory response. Annu. Rev. Immunol. 2010, 28:321-342.
43. Sarkisian C.J., Keister B.A., Stairs D.B., Boxer R.B., Moody S.E., Chodosh L.A. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 2007, 9:493-505.
44. Schwartz Y.B., Pirrotta V. A new world of Polycombs: unexpected partnerships and emerging functions. Nat. Rev. Genet. 2013, 14:853-864.
45. Schwartzentruber J., Korshunov A., Liu X.-Y., Jones D.T.W., Pfaff E., Jacob K., Sturm D., Fontebasso A.M., Quang D.-A.K., Tönjes M., et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012, 482:226-231.
46. Shao D.D., Xue W., Krall E.B., Bhutkar A., Piccioni F., Wang X., Schinzel A.C., Sood S., Rosenbluh J., Kim J.W., et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014, 158:171-184.
47. Singh M., Lima A., Molina R., Hamilton P., Clermont A.C., Devasthali V., Thompson J.D., Cheng J.H., Bou Reslan H., Ho C.C.K., et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 2010, 28:585-593.
48. Snitow M.E., Li S., Morley M.P., Rathi K., Lu M.M., Kadzik R.S., Stewart K.M., Morrisey E.E. Ezh2 represses the basal cell lineage during lung endoderm development. Development 2015, 142:108-117.
49. Snyder E.L., Watanabe H., Magendantz M., Hoersch S., Chen T.A., Wang D.G., Crowley D., Whittaker C.A., Meyerson M., Kimura S., et al. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol. Cell 2013, 50:185-199.
50. Su I.-H., Dobenecker M.-W., Dickinson E., Oser M., Basavaraj A., Marqueron R., Viale A., Reinberg D., Wülfing C., Tarakhovsky A. Polycomb group protein EZH2 controls actin polymerization and cell signaling. Cell 2005, 121:425-436.
51. Sugano M., Nagasaka T., Sasaki E., Murakami Y., Hosoda W., Hida T., Mitsudomi T., Yatabe Y. HNF4α as a marker for invasive mucinous adenocarcinoma of the lung. Am. J. Surg. Pathol. 2013, 37:211-218.
52. Sutherland K.D., Song J.-Y., Kwon M.C., Proost N., Zevenhoven J., Berns A. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc. Natl. Acad. Sci. USA 2014, 111:4952-4957.
53. Takawa M., Masuda K., Kunizaki M., Daigo Y., Takagi K., Iwai Y., Cho H.-S., Toyokawa G., Yamane Y., Maejima K., et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 2011, 102:1298-1305.
54. Tie F., Banerjee R., Stratton C.A., Prasad-Sinha J., Stepanik V., Zlobin A., Diaz M.O., Scacheri P.C., Harte P.J. CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing. Development 2009, 136:3131-3141.
55. Tiwari N., Tiwari V.K., Waldmeier L., Balwierz P.J., Arnold P., Pachkov M., Meyer-Schaller N., Schübeler D., van Nimwegen E., Christofori G. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling ezh2 expression and epigenetic reprogramming. Cancer Cell 2013, 23:768-783.
56. Vivanco I. Targeting molecular addictions in cancer. Br. J. Cancer 2014, 111:2033-2038.
57. Xie H., Xu J., Hsu J.H., Nguyen M., Fujiwara Y., Peng C., Orkin S.H. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell 2014, 14:68-80.
58. Yang M.-H., Hsu D.S.-S., Wang H.-W., Wang H.-J., Lan H.-Y., Yang W.-H., Huang C.-H., Kao S.-Y., Tzeng C.-H., Tai S.-K., et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat. Cell Biol. 2010, 12:982-992.
59. Zacharek S.J., Fillmore C.M., Lau A.N., Gludish D.W., Chou A., Ho J.W.K., Zamponi R., Gazit R., Bock C., Jäger N., et al. Lung stem cell self-renewal relies on BMI1-dependent control of expression at imprinted loci. Cell Stem Cell 2011, 9:272-281.
60. Zhang M., Wang Y., Jones S., Sausen M., McMahon K., Sharma R., Wang Q., Belzberg A.J., Chaichana K., Gallia G.L., et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Genet. 2014, 46:1170-1172.
61. Zheng Y., de la Cruz C.C., Sayles L.C., Alleyne-Chin C., Vaka D., Knaak T.D., Bigos M., Xu Y., Hoang C.D., et al. A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal. Cancer Cell 2013, 24:59-74.